Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-cash Items (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non-cash Items for 7 consecutive years, with $6.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-cash Items rose 45.4% to $6.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.0 million, a 45.4% increase, with the full-year FY2024 number at $54.5 million, up 1640.94% from a year prior.
  • Non-cash Items was $6.0 million for Q3 2025 at 4D Molecular Therapeutics, up from $5.5 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $54.5 million in Q4 2024 to a low of $1.4 million in Q2 2021.
  • A 5-year average of $11.6 million and a median of $3.3 million in 2024 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 74.6% in 2021, then soared 94.8% in 2022.
  • 4D Molecular Therapeutics' Non-cash Items stood at $24.7 million in 2021, then skyrocketed by 94.8% to $48.0 million in 2022, then fell by 2.47% to $46.9 million in 2023, then rose by 16.3% to $54.5 million in 2024, then crashed by 88.96% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Non-cash Items are $6.0 million (Q3 2025), $5.5 million (Q2 2025), and $5.0 million (Q1 2025).